Eli Lilly's Oral GLP-1 Drug Orforglipron Awaits Health Canada Review

Eli Lilly's experimental oral GLP-1 medication Orforglipron has not yet received approval from Health Canada, despite the company submitting the drug for FDA review in late 2025.

Current Regulatory Status

As of March 2026, Orforglipron remains under regulatory review by health authorities including Health Canada. The medication represents a potential new entry in the GLP-1 drug class, which currently includes injectable medications such as Ozempic, Wegovy, and Mounjaro.

The drug's oral formulation would differentiate it from existing GLP-1 medications in the Canadian market, most of which require injection. Health Canada recently approved Rybelsus, another oral GLP-1 medication from Novo Nordisk, marking the first daily pill option in this drug class for Canadian patients.

Eli Lilly's GLP-1 Portfolio in Canada

Eli Lilly currently markets tirzepatide-based medications in Canada, including Mounjaro for diabetes management. The company recently announced price reductions of up to 20% for these medications in the Canadian market. Orforglipron would represent a different compound entirely, potentially expanding treatment options for healthcare providers and patients.

The pharmaceutical company has not provided specific timelines for Health Canada submission or potential approval dates for Orforglipron in Canada. Regulatory approval processes typically involve extensive review of clinical trial data, manufacturing information, and safety profiles.

Canadian GLP-1 Market Landscape

The Canadian GLP-1 medication market is experiencing significant changes in 2026. Generic versions of semaglutide-based drugs are expected to enter the market following patent expiration in January 2026, with Health Canada currently reviewing nine generic applications from various manufacturers including Sandoz, Apotex, and Teva.

Survey data suggests approximately three million Canadian adults currently use GLP-1 medications. The addition of new oral formulations could potentially impact prescribing patterns and patient preferences, though specific market effects remain speculative pending regulatory approval.

Oral vs Injectable GLP-1 Options

Currently approved oral GLP-1 medications in Canada include Rybelsus (semaglutide), which received Health Canada approval for specific patient populations. Injectable options include various strengths and formulations of semaglutide and tirzepatide from Novo Nordisk and Eli Lilly respectively.

Patients seeking information about current GLP-1 medication options and pricing can use the insurance coverage checker to understand potential benefits coverage. Those interested in upcoming generic alternatives can monitor the generic semaglutide tracker for the latest regulatory updates.

Regulatory Timeline Considerations

Health Canada approval processes for new medications involve multiple review stages and can vary significantly in duration. The agency evaluates clinical trial data, manufacturing standards, labeling requirements, and post-market surveillance plans before granting market authorization.

Eli Lilly has not announced specific submission dates to Health Canada for Orforglipron. The company's existing regulatory relationships in Canada, including approvals for Mounjaro and Zepbound, may inform but do not guarantee timelines for new drug applications.

Healthcare providers and patients seeking current information about approved GLP-1 medications can consult the FAQ section for detailed information about available options, pricing, and coverage considerations.

This article is for informational purposes only and does not constitute medical advice.